In a randomized Phase 2b trial presented at EASD in Milan last week, Lilly’s EloraTZP (eloralintide, a selective amylin agonist, given with tirzepatide) produced 23.3% estimated weight loss at 48 weeks at its top dose, eloralintide 9 mg with tirzepatide 15 mg, in adults with obesity or overweight and type 2 diabetes. Tirzepatide 15 mg alone, in the same trial, produced 14.8%. That 8.5-percentage-point gap is the strongest thing in this data set, because it comes from a comparison within one randomized trial rather than across trials.
Weight loss has generally been smaller in trials enrolling people with type 2 diabetes, which makes that gap worth attention. It comes with qualifiers. The comparison with tirzepatide was secondary and reported without confidence intervals, the data are from a press release, and 23.3% is an efficacy estimand. And people in the combination arms stopped treatment for adverse events more often than those on tirzepatide alone. More weight loss, more people stopping: that is the tension to resolve.
| Clinical Takeaway | |||||||||||||||
|
